ASO Author Reflections: Novel Evidence on Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Cancer with Arterial Involvement

被引：0
|
作者：
Ikenaga, Naoki [1 ]
Miyasaka, Yoshihiro [2 ]
Ohtsuka, Takao [3 ]
Nakamura, Masafumi [1 ]
机构：
[1] Kyushu Univ, Grad Sch Med Sci, Dept Surg & Oncol, Fukuoka, Japan
[2] Fukuoka Univ, Chikushi Hosp, Dept Surg, Chikushino, Japan
[3] Kagoshima Univ, Grad Sch Med Sci, Digest Surg Breast & Thyroid Surg, Kagoshima, Japan
来源：
ANNALS OF SURGICAL ONCOLOGY | 2023年 / 30卷 / 01期
关键词：
D O I：
10.1245/s10434-022-12584-z
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：203 / 204
页数：2
相关论文
共 50 条
  • [1] ASO Author Reflections: Novel Evidence on Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Cancer with Arterial Involvement
    Naoki Ikenaga
    Yoshihiro Miyasaka
    Takao Ohtsuka
    Masafumi Nakamura
    Annals of Surgical Oncology, 2023, 30 : 203 - 204
  • [2] ASO Author Reflections: Is There an Extra Benefit of Adding Neoadjuvant Radiotherapy to Chemotherapy in Patients with (Borderline) Resectable Pancreatic Cancer?
    Yun, Won-Gun
    Jang, Jin-Young
    ANNALS OF SURGICAL ONCOLOGY, 2025, 32 (04) : 2859 - 2860
  • [3] ASO Author Reflections: Neoadjuvant Therapy for Borderline Resectable Pancreatic Cancer: Is Combined Radiotherapy Necessary?
    Yuichi Nagakawa
    Annals of Surgical Oncology, 2019, 26 : 1637 - 1638
  • [4] ASO Author Reflections: Neoadjuvant Therapy for Borderline Resectable Pancreatic Cancer: Is Combined Radiotherapy Necessary?
    Nagakawa, Yuichi
    ANNALS OF SURGICAL ONCOLOGY, 2019, 26 (06) : 1637 - 1638
  • [5] ASO Author Reflections: Impact of Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Borderline Resectable Pancreatic Cancer on Surgical Outcomes
    Miyasaka, Yoshihiro
    Nakamura, Masafumi
    ANNALS OF SURGICAL ONCOLOGY, 2019, 26 (Suppl 3) : S739 - S740
  • [6] ASO Author Reflections: Impact of Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Borderline Resectable Pancreatic Cancer on Surgical Outcomes
    Yoshihiro Miyasaka
    Masafumi Nakamura
    Annals of Surgical Oncology, 2019, 26 : 739 - 740
  • [7] ASO Author Reflections: Chemotherapy Regimen in Borderline Resectable and Locally Advanced Pancreatic Cancer—Resection Cuts the Deal
    Dilmurodjon Eshmuminov
    Botirjon Aminjonov
    Russell F. Palm
    Kuno Lehmann
    Annals of Surgical Oncology, 2023, 30 : 4429 - 4430
  • [8] ASO Author Reflections: Chemotherapy Regimen in Borderline Resectable and Locally Advanced Pancreatic Cancer-Resection Cuts the Deal
    Eshmuminov, Dilmurodjon
    Aminjonov, Botirjon
    Palm, Russell F.
    Lehmann, Kuno
    ANNALS OF SURGICAL ONCOLOGY, 2023, 30 (07) : 4429 - 4430
  • [9] ASO Author Reflections: Total Neoadjuvant Therapy with Chemotherapy Alone for Pancreatic Cancer?
    Miller, Phoebe N.
    Nakakura, Eric K.
    ANNALS OF SURGICAL ONCOLOGY, 2024, 31 (09) : 6203 - 6204
  • [10] ASO Visual Abstract: Neoadjuvant Chemotherapy Switch in Borderline Resectable/Locally Advanced Pancreatic Cancer
    Alva-Ruiz, Roberto
    Yohanathan, Lavanya
    Yonkus, Jennifer A.
    Abdelrahman, Amro M.
    Gregory, Lindsey A.
    Halfdanarson, Thorvadur R.
    Mahipal, Amit
    McWilliams, Robert R.
    Ma, Wen Wee
    Hallemeier, Christopher L.
    Graham, Rondell P.
    Grotz, Travis E.
    Smoot, Rory L.
    Cleary, Sean P.
    Nagorney, David M.
    Kendrick, Michael L.
    Truty, Mark J.
    ANNALS OF SURGICAL ONCOLOGY, 2022, 29 (03) : 1594 - 1595
12345